Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
Department of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.
Front Endocrinol (Lausanne). 2022 Jan 18;12:802419. doi: 10.3389/fendo.2021.802419. eCollection 2021.
Tandem Control-IQ and Minimed 780G represent the most Advanced Hybrid Closed Loop (AHCL) systems currently available in pediatric and adult subjects with Type 1 Diabetes (T1D). We retrospectively compared clinical and continuous glucose monitoring data from 51 patients who upgraded to Minimed 780G system and have completed 1-month observation period with data from 39 patients who upgraded to Tandem Control-IQ. Inverse probability weighting was used to minimize the basal characteristics imbalances. Both AHCL systems showed a significant improvement in glycemic parameters. Minimed 780G group achieved higher TIR increase (p= 0.004) and greater reduction of blood glucose average (p= 0.001). Tandem Control-IQ system significantly reduced the occurrence of TBR (p= 0.010) and the Coefficient of Variation of glucose levels (p= 0.005). The use of ACHL systems led to a significant improvement of glycemic control substantially reaching the International recommended glycemic targets. Minimed 780G appears to be more effective in managing hyperglycemia, while Tandem Control-IQ seems to be more effective in reducing time in hypoglycemia.
Tandem Control-IQ 和 Minimed 780G 代表了目前在 1 型糖尿病(T1D)的儿科和成人患者中最先进的混合闭环(AHCL)系统。我们回顾性比较了 51 名升级到 Minimed 780G 系统并完成了 1 个月观察期的患者与 39 名升级到 Tandem Control-IQ 的患者的临床和连续血糖监测数据。采用逆概率加权法最小化基础特征的不平衡。两种 AHCL 系统均显著改善了血糖参数。Minimed 780G 组实现了更高的 TIR 增加(p=0.004)和更低的血糖平均值(p=0.001)。Tandem Control-IQ 系统显著降低了 TBR 的发生(p=0.010)和血糖水平的变异系数(p=0.005)。使用 AHCL 系统可显著改善血糖控制,几乎达到国际推荐的血糖目标。Minimed 780G 似乎在控制高血糖方面更有效,而 Tandem Control-IQ 似乎在降低低血糖时间方面更有效。